Erratum to: High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. - Kelaidi, C.; Beyne-Rauzy, O.; Braun, T.; Sapena, R.; Cougoul, P.; Adès, L.; Pillard, F.; Lamberto, C.; Charniot, J.; Guerci, A.; Choufi, B.; Stamatoullas, A.; et al. (Annals of Hematology, 2013)